% | $
Quotes you view appear here for quick access.

OxySure Therapeutics, Inc. Message Board

  • paul462123 paul462123 Oct 15, 2013 11:01 AM Flag

    OxySure Launches Commercial Finance

    FRISCO, TX, Oct 15, 2013 (Marketwired via COMTEX) -- OxySure Systems, Inc. (otcqb:OXYS) ("OxySure" or the "Company"), a medical technology company that has pioneered an FDA-approved solution to produce medically pure oxygen from dry, inert powders for emergency and short duration use, today announced the launch of OxySure Commercial Finance(SM) , a service that allows OxySure customers to easily and conveniently lease OxySure's suite of medical devices and products, including the OxySure Model 615, Automated External Defibrillators (AEDs), and other medical equipment, supplies and accessories.

    Powered by LeaseQ, OxySure Commercial Finance(SM) allows customers to do comparison shopping for lease quotes from dozens of third party lenders with one simple online form that takes two minutes to complete. The system can pre-qualify customers instantly and display the top results, allowing customers to select from multiple, pre-qualified offers. The system also provides customers the flexibility to select lenders of choice and payment plan characteristics such as monthly payment, finance term and terminal value.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • What's your take on this, Paul?

      Sentiment: Strong Buy

    • OXYS should be focusing on sales not financing these low cost items-------there are some sites that are selling model 615 for $275.

      They have minimal sales to individuals as they are focusing on adding distributors which are not focused on is obvious since there are over 4 distributors and sales in the last quarter did not even total $500,000.

      It is shocking how weak management is.

      • 1 Reply to jim1518
      • Jim - I'm all for hearing the good and the bad, but I think you're being a bit harsh and unrealistic. The product is still, for the most part, an unknown, something that has never been sold before. It wasn't too long ago that the company got FDA approval to sell it. They are still in the process of getting approval in Europe. Yes, sales were about what you quote, but compared to the quarter proceeding that, they moved up markedly. I'm not sure about these latest announcement. It does seem a bit gimmicky to me. But if it helps just a bit to make it easier to purchase the 615, I guess it's worth it. Doesn't appear the company has made any type of cash investment to provide this service. Merely, partnering with financial service companies which can offer financing for a purchase. Anyway, I expect sales to grow again this upcoming reporting quarter. If we see flat or meager growth, I'm in your camp. As for management, don't you think having this Jones guy on the board is a plus?

        Sentiment: Strong Buy

0.020.00(-3.12%)Aug 23 2:03 PMEDT